NJ Doctor Serge Menkin Loses DEA Registration Permanently
Published Date: 6/10/2025
Notice
Summary
Dr. Serge Menkin from New Jersey lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of January 31, 2025. This means Dr. Menkin can’t legally work with controlled drugs anymore, and the decision is final.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Menkin
The Drug Enforcement Administration revoked Serge Menkin, M.D.'s DEA Certificate of Registration No. BM8723795. The revocation is effective July 10, 2025, and follows findings that he is not authorized to handle controlled substances in New Jersey; his DEA registration had expired on January 31, 2025.
Pending and New New Jersey Registrations Denied
The Order denies any pending applications by Serge Menkin, M.D., to renew or modify his DEA registration and also denies any other pending application he has for additional registration in New Jersey. This denial is issued pursuant to the same Order effective July 10, 2025.
15-Day Reconsideration Right to Dispute Fact
The Order gives Serge Menkin, M.D., the right to file a properly supported motion for reconsideration of the Agency's factual finding that he lacks authority to handle controlled substances in New Jersey. Any such motion must be filed within fifteen calendar days of the date of the Order and served by email to the DEA Office of the Administrator at [email protected].
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Previous / Next Documents
Previous: 2025-10501 — Harry Kram, M.D.; Decision and Order
Dr. Harry Kram from California lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite being notified, he didn’t ask for a hearing, so the DEA officially revoked his registration by default. This means Dr. Kram can’t legally prescribe or handle controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Next: 2025-10504 — Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the Alaska Department of Transportation and Public Facilities Angoon Ferry Terminal Modification Project in Angoon, Alaska
The Alaska Department of Transportation is updating the Angoon Ferry Terminal in Alaska, and this work might accidentally bother some marine mammals nearby. They've got permission to do this safely without hurting the animals, following important rules. The project will happen soon and aims to improve ferry services while protecting wildlife.